These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://emilieydoj000263.alltdesign.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-57845876